Key Highlights
- $1.6 million grant awarded to Surf Bio, Inc. by the Bill & Melinda Gates Foundation.
- The grant will support the evaluation of Surf Bio’s polymer technology for stabilizing monoclonal antibodies in low- and middle-income countries.
- Potential to eliminate refrigeration needs and enable subcutaneous administration of biologics, enhancing accessibility.
Source: Business Wire
Notable Quote
- “We are thrilled to receive support from the Bill & Melinda Gates Foundation to advance the use of our technology to enable greater access to biologics in low- and middle-income countries.” – Bryan Mazlish, Co-founder and CEO at Surf Bio
SoHC's Take
Surf Bio’s innovative approach could revolutionize the delivery and stability of biologic medicines in regions where refrigeration is a major barrier to healthcare. This grant will enable further evaluation of the technology, potentially making biologics more accessible and affordable in these vital areas. The collaboration with leading pharmaceutical companies further validates the promising applications of Surf Bio’s platform, suggesting a substantial impact on global health if successful.
